

Joseph A Dimasi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4039270/joseph-a-dimasi-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

7,377
citations

25
h-index

52
g-index

52
ext. papers

8,742
ext. citations

7.1
avg, IF

6.43
L-index

#	Paper	IF	Citations
46	The price of innovation: new estimates of drug development costs. <i>Journal of Health Economics</i> , 2003 , 22, 151-85	3.5	2816
45	Innovation in the pharmaceutical industry: New estimates of R&D costs. <i>Journal of Health Economics</i> , 2016 , 47, 20-33	3.5	1486
44	Cost of innovation in the pharmaceutical industry. <i>Journal of Health Economics</i> , 1991 , 10, 107-42	3.5	451
43	The cost of biopharmaceutical R&D: is biotech different?. <i>Managerial and Decision Economics</i> , 2007 , 28, 469-479	1.1	329
42	Risks in new drug development: approval success rates for investigational drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 297-307	6.1	297
41	Economics of new oncology drug development. <i>Journal of Clinical Oncology</i> , 2007 , 25, 209-16	2.2	271
40	Returns on research and development for 1990s new drug introductions. <i>Pharmacoeconomics</i> , 2002 , 20 Suppl 3, 11-29	4.4	177
39	New drug development in the United States from 1963 to 1999. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 286-96	6.1	167
38	The value of improving the productivity of the drug development process: faster times and better decisions. <i>Pharmacoeconomics</i> , 2002 , 20 Suppl 3, 1-10	4.4	148
37	Success rates for new drugs entering clinical testing in the United States. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 58, 1-14	6.1	139
36	The economics of follow-on drug research and development: trends in entry rates and the timing of development. <i>Pharmacoeconomics</i> , 2004 , 22, 1-14	4.4	124
35	Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. <i>Pharmacoeconomics</i> , 1995 , 7, 152-69	4.4	89
34	Competitiveness in follow-on drug R&D: a race or imitation?. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 23-7	64.1	75
33	The cost of drug development. <i>New England Journal of Medicine</i> , 2015 , 372, 1972	59.2	73
32	R&D Costs and Returns by Therapeutic Category. <i>Drug Information Journal</i> , 2004 , 38, 211-223		63
31	Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. <i>Therapeutic Innovation and Regulatory Science</i> , 2018 , 52, 220-229	1.2	62
30	Drug development costs when financial risk is measured using the Fama-French three-factor model. <i>Health Economics (United Kingdom)</i> , 2010 , 19, 1002-5	2.4	61

29	New drug development in the United States from 1963 to 1992. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 609-22	6.1	55
28	Emerging role of pharmacoeconomics in the research and development decision-making process. <i>Pharmacoeconomics</i> , 2001 , 19, 753-66	4.4	40
27	New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms. <i>Drug Information Journal</i> , 2000 , 34, 1169-1194		39
26	R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry. <i>International Journal of the Economics of Business</i> , 1995 , 2, 201-219	0.9	39
25	The roles of patents and research and development incentives in biopharmaceutical innovation. <i>Health Affairs</i> , 2015 , 34, 302-10	7	36
24	Measuring the Pace of New Drug Development in the User Fee ERA. <i>Drug Information Journal</i> , 2000 , 34, 673-680		28
23	New drug development in the United States from 1963 to 1990. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 471-86	6.1	26
22	Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years: From Theory to Therapy. <i>Therapeutic Innovation and Regulatory Science</i> , 2016 , 50, 759-768	1.2	26
21	Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. <i>Clinical Therapeutics</i> , 2013 , 35, 808-18	3.5	24
20	Pharmaceutical R&D performance by firm size: approval success rates and economic returns. <i>American Journal of Therapeutics</i> , 2014 , 21, 26-34	1	23
19	Extraordinary claims require extraordinary evidence. <i>Journal of Health Economics</i> , 2005 , 24, 1034-1044	3.5	23
18	Setting the record straight on setting the record straight: Response to the Light and Warburton rejoinder. <i>Journal of Health Economics</i> , 2005 , 24, 1049-1053	3.5	17
17	Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 608-18	6.1	16
16	Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities. <i>Clinical Therapeutics</i> , 2017 , 39, 1409-1425.e20	3.5	15
15	Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 324-332	6.1	14
14	Initiatives to Speed New Drug Development and Regulatory Review: The Impact of FDA-Sponsor Conferences. <i>Drug Information Journal</i> , 1997 , 31, 771-788		12
13	Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial. <i>Clinical Infectious Diseases</i> , 2018 , 66, 72-80	11.6	11
12	Assessing Pharmaceutical Research and Development Costs. <i>JAMA Internal Medicine</i> , 2018 , 178, 587	11.5	11

11	The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times. <i>Therapeutic Innovation and Regulatory Science</i> , 2014 , 48, 482-487	1.2	11
10	R&D Costs and Returns to New Drug Development: A Review of the Evidence 2012 ,		8
9	New indications for already-approved drugs: an analysis of regulatory review times. <i>Journal of Clinical Pharmacology</i> , 1991 , 31, 205-15	2.9	6
8	Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical Manufacturing. <i>Clinical Therapeutics</i> , 2018 , 40, 963-972	3.5	4
7	An Analysis of Regulatory Review Times of Supplemental Indications for Already-Approved Drugs: 1989-1994. <i>Drug Information Journal</i> , 1996 , 30, 315-337		4
6	The economics of follow-on drug research and development: Trends in entry rates and the timing of development [The authors]reply. <i>Pharmacoeconomics</i> , 2005 , 23, 1193-1202	4.4	3
5	Analysis of Review Times for Recent 505(b)(2) Applications. <i>Therapeutic Innovation and Regulatory Science</i> , 2017 , 51, 651-656	1.2	2
4	The Financial Benefits of Faster Development Times: Integrated Formulation Development, Real-Time Manufacturing, and Clinical Testing. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 1453-1460	1.2	2
3	Mandatory comparator trials for therapeutically similar drugs: an assessment of the facts. <i>American Journal of Therapeutics</i> , 2007 , 14, 231-4	1	2
2	Research and Development Costs of New Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 517	27.4	1
1	Impact of Comparative Effectiveness Research on Drug Development Strategy and Innovation 2017 , 63-73		